引用本文
  • 汪海潮,叶 晨,王晓蕾.难治性中重度溃疡性结肠炎的生物制剂治疗研究进展[J].同济大学学报(医学版),2020,41(1):136-140.    [点击复制]
  • WANG Hai-chao,YE Chen,WANG Xiao-lei.Research advances of biological therapy for refractory moderate to severe ulcerative colitis[J].同济大学学报(医学版),2020,41(1):136-140.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 12次   下载 13 本文二维码信息
码上扫一扫!
难治性中重度溃疡性结肠炎的生物制剂治疗研究进展
汪海潮,叶晨,王晓蕾
0
(同济大学附属第十人民医院消化内科,上海 200072; 苏州大学医学部,江苏 苏州 215000)
摘要:
溃疡性结肠炎(ulcerative colitis, UC)是炎症性肠病的一种表现形式,可导致严重不良后果。临床常规用药包括氨基水杨酸制剂、糖皮质激素、免疫抑制剂,但仍有部分难治性中重度UC患者对常规治疗无效,需要转换至生物制剂治疗。目前用于临床治疗UC有效的生物制剂有3类(抗肿瘤坏死因子-α抗体、抗整合素α4β7制剂、肌酸激酶抑制剂)。本文旨在从药物作用机制、疗效及不良反应等方面总结各生物制剂治疗难治性中重度UC的特点,为临床用药提供参考。
关键词:  溃疡性结肠炎  生物制剂  抗TNF-α类药物  抗整合素制剂  JAK抑制剂
DOI:10.16118/j.1008-0392.2020.01.024
投稿时间:2019-03-07
基金项目:国家自然科学基金面上项目(81670476)
Research advances of biological therapy for refractory moderate to severe ulcerative colitis
WANG Hai-chao,YE Chen,WANG Xiao-lei
(Dept. of Gastroenterology, Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China;Dept. of Gastroenterology, Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China; Medical College of Soochow University, Suzhou 215000, Jiangsu Province, China)
Abstract:
Ulcerative colitis(UC) is a kind of inflammatory bowel disease(IBD), which can result in significant morbidity. Routine clinical drugs(including aminosalicylates, corticosteroids and immunosuppressive agents) are effective in most cases, but some patients with refractory moderate to severe UC are still ineffective with conventional treatment and need to be transferred to biological agents. At present, the anti-TNF-α antibodies, anti-integrin α4β7 and Janus kinase(JAK) inhibitor are effective biological agents for the treatment of refractory moderate to severe UC. This article reviews the characteristics of related biological agents to provide reference for treatment of refractory UC.
Key words:  ulcerative colitis  biological agents  anti-TNF-α antibodies  anti-integrin α4β7  Janus kinase inhibitor

您是第1829464位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计